TransMedics Group, Inc. (NASDAQ:TMDX) Stock Position Raised by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 5.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 599,116 shares of the company's stock after acquiring an additional 30,092 shares during the period. Allspring Global Investments Holdings LLC owned about 1.82% of TransMedics Group worth $94,061,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in shares of TransMedics Group by 10.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company's stock valued at $31,358,000 after acquiring an additional 38,951 shares during the period. Vanguard Group Inc. grew its position in TransMedics Group by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company's stock worth $147,214,000 after purchasing an additional 50,673 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new position in TransMedics Group in the 2nd quarter worth about $1,400,000. Handelsbanken Fonder AB increased its stake in shares of TransMedics Group by 657.6% in the third quarter. Handelsbanken Fonder AB now owns 64,400 shares of the company's stock valued at $10,111,000 after purchasing an additional 55,900 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in shares of TransMedics Group by 337,462.5% during the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company's stock valued at $1,997,000 after buying an additional 26,997 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

TransMedics Group Price Performance

Shares of NASDAQ TMDX traded down $2.12 during midday trading on Monday, reaching $124.48. The company's stock had a trading volume of 1,192,392 shares, compared to its average volume of 835,844. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $177.37. The company has a market cap of $4.15 billion, a price-to-earnings ratio of 3,112.00 and a beta of 1.99. The company has a 50 day moving average price of $151.92 and a 200 day moving average price of $139.08. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analysts' expectations of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The firm's revenue was up 117.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.03) earnings per share. On average, equities research analysts expect that TransMedics Group, Inc. will post 1.22 EPS for the current year.

Insider Activity

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the business's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the sale, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Edward M. Basile sold 6,750 shares of the firm's stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $149.96, for a total value of $1,012,230.00. Following the completion of the sale, the director now owns 732 shares of the company's stock, valued at $109,770.72. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Tamer I. Khayal sold 2,958 shares of the company's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at $3,267,557.11. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,205 shares of company stock valued at $9,981,907 over the last three months. Insiders own 7.00% of the company's stock.

Analyst Ratings Changes

TMDX has been the subject of a number of recent analyst reports. Robert W. Baird initiated coverage on TransMedics Group in a report on Tuesday, September 24th. They issued an "outperform" rating and a $200.00 price objective for the company. Piper Sandler reissued an "overweight" rating and set a $180.00 price target on shares of TransMedics Group in a report on Monday, October 7th. Morgan Stanley lifted their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the company an "equal weight" rating in a research note on Monday, July 15th. Oppenheimer increased their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the company an "outperform" rating in a research report on Thursday, August 1st. Finally, Baird R W upgraded shares of TransMedics Group to a "strong-buy" rating in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $174.30.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.